Selected research
Market Structure
Global Hepatitis A immunoglobulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Hepatitis A immunoglobulin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Hepatitis A immunoglobulin include CSL Behring, Dr. Reddy's Laboratories, Native Antigen, AIM Vaccine, GSK, Sinovac Biotech, Merck, Pukang Biotechnology and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Hepatitis A immunoglobulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hepatitis A immunoglobulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hepatitis A immunoglobulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis A immunoglobulin market size, projected growth trends, production technologies, key applications, and end-use industries.
Hepatitis A immunoglobulin Segment by Company
CSL Behring
Dr. Reddy's Laboratories
Native Antigen
AIM Vaccine
GSK
Sinovac Biotech
Merck
Pukang Biotechnology
Sanofi
Changchun Lnstitute Of Biological Products
Zhifei Biological Products
Hepatitis A immunoglobulin Segment by Type
Inactivated
Attenuated
Hepatitis A immunoglobulin Segment by Application
Hospital
Pharmacy
Other
Hepatitis A immunoglobulin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A immunoglobulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A immunoglobulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A immunoglobulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hepatitis A immunoglobulin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis A immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatitis A immunoglobulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hepatitis A immunoglobulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated
- Attenuated
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- CSL Behring
- Dr. Reddy's Laboratories
- Native Antigen
- AIM Vaccine
- GSK
- Sinovac Biotech
- Merck
- Pukang Biotechnology
- Sanofi
- Changchun Lnstitute Of Biological Products
- Zhifei Biological Products
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hepatitis A immunoglobulin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hepatitis A immunoglobulin Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hepatitis A immunoglobulin Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hepatitis A immunoglobulin Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hepatitis A immunoglobulin Market Dynamics
- 2.1 Hepatitis A immunoglobulin Industry Trends
- 2.2 Hepatitis A immunoglobulin Industry Drivers
- 2.3 Hepatitis A immunoglobulin Industry Opportunities and Challenges
- 2.4 Hepatitis A immunoglobulin Industry Restraints
3 Hepatitis A immunoglobulin Market by Manufacturers
- 3.1 Global Hepatitis A immunoglobulin Revenue by Manufacturers (2021-2026)
- 3.2 Global Hepatitis A immunoglobulin Sales by Manufacturers (2021-2026)
- 3.3 Global Hepatitis A immunoglobulin Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hepatitis A immunoglobulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hepatitis A immunoglobulin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hepatitis A immunoglobulin Manufacturers, Product Type & Application
- 3.7 Global Hepatitis A immunoglobulin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hepatitis A immunoglobulin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hepatitis A immunoglobulin Players Market Share by Revenue in 2025
- 3.8.3 2025 Hepatitis A immunoglobulin Tier 1, Tier 2, and Tier 3
4 Hepatitis A immunoglobulin Market by Type
- 4.1 Hepatitis A immunoglobulin Type Introduction
- 4.1.1 Inactivated
- 4.1.2 Attenuated
- 4.2 Global Hepatitis A immunoglobulin Sales by Type
- 4.2.1 Global Hepatitis A immunoglobulin Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hepatitis A immunoglobulin Sales by Type (2021-2032)
- 4.2.3 Global Hepatitis A immunoglobulin Sales Market Share by Type (2021-2032)
- 4.3 Global Hepatitis A immunoglobulin Revenue by Type
- 4.3.1 Global Hepatitis A immunoglobulin Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hepatitis A immunoglobulin Revenue by Type (2021-2032)
- 4.3.3 Global Hepatitis A immunoglobulin Revenue Market Share by Type (2021-2032)
5 Hepatitis A immunoglobulin Market by Application
- 5.1 Hepatitis A immunoglobulin Application Introduction
- 5.1.1 Hospital
- 5.1.2 Pharmacy
- 5.1.3 Other
- 5.2 Global Hepatitis A immunoglobulin Sales by Application
- 5.2.1 Global Hepatitis A immunoglobulin Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hepatitis A immunoglobulin Sales by Application (2021-2032)
- 5.2.3 Global Hepatitis A immunoglobulin Sales Market Share by Application (2021-2032)
- 5.3 Global Hepatitis A immunoglobulin Revenue by Application
- 5.3.1 Global Hepatitis A immunoglobulin Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hepatitis A immunoglobulin Revenue by Application (2021-2032)
- 5.3.3 Global Hepatitis A immunoglobulin Revenue Market Share by Application (2021-2032)
6 Global Hepatitis A immunoglobulin Sales by Region
- 6.1 Global Hepatitis A immunoglobulin Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hepatitis A immunoglobulin Sales by Region (2021-2032)
- 6.2.1 Global Hepatitis A immunoglobulin Sales by Region (2021-2026)
- 6.2.2 Global Hepatitis A immunoglobulin Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hepatitis A immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hepatitis A immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hepatitis A immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hepatitis A immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hepatitis A immunoglobulin Revenue by Region
- 7.1 Global Hepatitis A immunoglobulin Revenue by Region
- 7.1.1 Global Hepatitis A immunoglobulin Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hepatitis A immunoglobulin Revenue by Region (2021-2026)
- 7.1.3 Global Hepatitis A immunoglobulin Revenue by Region (2027-2032)
- 7.1.4 Global Hepatitis A immunoglobulin Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hepatitis A immunoglobulin Revenue (2021-2032)
- 7.2.2 North America Hepatitis A immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hepatitis A immunoglobulin Revenue (2021-2032)
- 7.3.2 Europe Hepatitis A immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hepatitis A immunoglobulin Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hepatitis A immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hepatitis A immunoglobulin Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hepatitis A immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSL Behring
- 8.1.1 CSL Behring Company Information
- 8.1.2 CSL Behring Business Overview
- 8.1.3 CSL Behring Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSL Behring Hepatitis A immunoglobulin Product Portfolio
- 8.1.5 CSL Behring Recent Developments
- 8.2 Dr. Reddy's Laboratories
- 8.2.1 Dr. Reddy's Laboratories Company Information
- 8.2.2 Dr. Reddy's Laboratories Business Overview
- 8.2.3 Dr. Reddy's Laboratories Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Dr. Reddy's Laboratories Hepatitis A immunoglobulin Product Portfolio
- 8.2.5 Dr. Reddy's Laboratories Recent Developments
- 8.3 Native Antigen
- 8.3.1 Native Antigen Company Information
- 8.3.2 Native Antigen Business Overview
- 8.3.3 Native Antigen Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Native Antigen Hepatitis A immunoglobulin Product Portfolio
- 8.3.5 Native Antigen Recent Developments
- 8.4 AIM Vaccine
- 8.4.1 AIM Vaccine Company Information
- 8.4.2 AIM Vaccine Business Overview
- 8.4.3 AIM Vaccine Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 AIM Vaccine Hepatitis A immunoglobulin Product Portfolio
- 8.4.5 AIM Vaccine Recent Developments
- 8.5 GSK
- 8.5.1 GSK Company Information
- 8.5.2 GSK Business Overview
- 8.5.3 GSK Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 GSK Hepatitis A immunoglobulin Product Portfolio
- 8.5.5 GSK Recent Developments
- 8.6 Sinovac Biotech
- 8.6.1 Sinovac Biotech Company Information
- 8.6.2 Sinovac Biotech Business Overview
- 8.6.3 Sinovac Biotech Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Sinovac Biotech Hepatitis A immunoglobulin Product Portfolio
- 8.6.5 Sinovac Biotech Recent Developments
- 8.7 Merck
- 8.7.1 Merck Company Information
- 8.7.2 Merck Business Overview
- 8.7.3 Merck Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Merck Hepatitis A immunoglobulin Product Portfolio
- 8.7.5 Merck Recent Developments
- 8.8 Pukang Biotechnology
- 8.8.1 Pukang Biotechnology Company Information
- 8.8.2 Pukang Biotechnology Business Overview
- 8.8.3 Pukang Biotechnology Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pukang Biotechnology Hepatitis A immunoglobulin Product Portfolio
- 8.8.5 Pukang Biotechnology Recent Developments
- 8.9 Sanofi
- 8.9.1 Sanofi Company Information
- 8.9.2 Sanofi Business Overview
- 8.9.3 Sanofi Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Sanofi Hepatitis A immunoglobulin Product Portfolio
- 8.9.5 Sanofi Recent Developments
- 8.10 Changchun Lnstitute Of Biological Products
- 8.10.1 Changchun Lnstitute Of Biological Products Company Information
- 8.10.2 Changchun Lnstitute Of Biological Products Business Overview
- 8.10.3 Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Product Portfolio
- 8.10.5 Changchun Lnstitute Of Biological Products Recent Developments
- 8.11 Zhifei Biological Products
- 8.11.1 Zhifei Biological Products Company Information
- 8.11.2 Zhifei Biological Products Business Overview
- 8.11.3 Zhifei Biological Products Hepatitis A immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Zhifei Biological Products Hepatitis A immunoglobulin Product Portfolio
- 8.11.5 Zhifei Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hepatitis A immunoglobulin Value Chain Analysis
- 9.1.1 Hepatitis A immunoglobulin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hepatitis A immunoglobulin Production Mode & Process
- 9.2 Hepatitis A immunoglobulin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hepatitis A immunoglobulin Distributors
- 9.2.3 Hepatitis A immunoglobulin Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst